Special Issue

The Mouse Xenograft Model in Cancer Research

Message from the Guest Editor

Human-to-mouse cancer xenografts are commonly used in cancer research to study the effectiveness of new treatments and to gain a better understanding of cancer biology. Xenografts can be made from a wide range of human cancers, including breast, prostate, lung and colon cancers. They can also be used to study the effects of different cancer therapies, such as chemotherapy, radiotherapy and immunotherapy, in a living organism. However, there are limitations to this technique. These models cannot recapitulate the complex interactions between tumour cells, stroma and the human immune system. In addition, the use of animal models raises ethical concerns, and there is an ongoing debate about the validity of using animal models to study human diseases. In this context, this Special Issue aims to bring the attention of Cancers readers to advances, cutting-edge developments, expertise and know-how across all cancer types in regard to these valuable animal models of cancer. Thus, we cordially invite authors to submit original articles, reviews and opinions that highlight their potential as tools for basic, translational and even precision medicine.

Guest Editor

Dr. Konstantinos Dimas

Department of Pharmacology, University of Thessaly, Biopolis, 41500 Larissa, Greece

Deadline for manuscript submissions

closed (15 July 2024)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/172082

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

